Literature DB >> 18832259

Erdosteine for COPD exacerbations.

.   

Abstract

The mucolytic drug erdosteine (Erdotin - Galen) is licensed in the UK as treatment for up to 10 days "for the symptomatic treatment of acute exacerbations of chronic bronchitis in adults". This indication differs from that for carbocisteine and mecysteine, two older mucolytic drugs that are licensed for adjunctive treatment in respiratory disorders characterised by viscous mucus, and typically used for longer to prevent exacerbations of chronic obstructive pulmonary disease (COPD). Does erdosteine have a role for people with COPD exacerbations?

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832259     DOI: 10.1136/dtb.2008.09.0024

Source DB:  PubMed          Journal:  Drug Ther Bull        ISSN: 0012-6543


  2 in total

1.  Erdosteine therapy for renal failure: current perspectives.

Authors:  Arunachalam Muthuraman
Journal:  Nephrourol Mon       Date:  2012-06-20

Review 2.  Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?

Authors:  Francesco Scaglione; Orlando Petrini
Journal:  Clin Med Insights Ear Nose Throat       Date:  2019-01-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.